Personalized Depression Treatment Explained In Fewer Than 140 Characters > 자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications don't work for a majority of patients suffering from depression. The individual approach to treatment could be the answer.

Cue is an intervention platform that transforms passively acquired sensor data from smartphones into personalised micro-interventions for improving mental depression treatment health. We analysed the best-fit personalized ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that are able to change mood with time.

Predictors of Mood

Depression is a leading cause of mental illness across the world.1 Yet only half of those with the condition receive treatment. To improve outcomes, clinicians must be able identify and treat patients who are most likely to respond to specific treatments.

The treatment of depression can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from specific treatments. They use sensors on mobile phones, a voice assistant with artificial intelligence and other digital tools. With two grants totaling over $10 million, they will employ these technologies to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

The majority of research into predictors of depression treatment effectiveness has focused on sociodemographic and clinical characteristics. These include demographics such as age, gender and education and clinical characteristics such as symptom severity, comorbidities and biological markers.

While many of these factors can be predicted from the information in medical records, few studies have used longitudinal data to determine the factors that influence mood in people. Few studies also take into account the fact that mood can differ significantly between individuals. Therefore, it is critical to create methods that allow the determination of individual differences in mood predictors and the effects of treatment.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to detect patterns of behaviour and emotions that are unique to each person.

The team also created a machine learning algorithm to create dynamic predictors for each person's mood for depression. The algorithm combines these individual variations into a distinct "digital phenotype" for each participant.

This digital phenotype was correlated with CAT DI scores, a psychometrically validated severity scale for symptom severity. However the correlation was not strong (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 yet it is often underdiagnosed and undertreated2. In addition, a lack of effective treatments and stigma associated with depressive disorders prevent many people from seeking help.

To allow for individualized treatment to improve treatment, identifying the factors that predict the severity of symptoms is crucial. The current prediction methods rely heavily on clinical interviews, which are not reliable and only identify a handful of symptoms associated with depression.

Machine learning can improve the accuracy of diagnosis and treatment for depression by combining continuous digital behavioral phenotypes gathered from smartphones with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes allow continuous, high-resolution measurements and capture a wide variety of distinct behaviors and patterns that are difficult to capture using interviews.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29 developed as part of the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics according to the severity of their depression. Participants with a CAT-DI score of 35 or 65 were assigned online support with a coach and those with a score 75 patients were referred for in-person psychotherapy.

At baseline, participants provided the answers to a series of questions concerning their personal characteristics and psychosocial traits. These included sex, age education, work, and financial status; if they were partnered, divorced or single; the frequency of suicidal ideation, intent, or attempts; and the frequency with that they consumed alcohol. The CAT-DI was used to rate the severity of depression-related symptoms on a scale of 0-100. The CAT-DI assessment was performed every two weeks for those who received online support and weekly for those who received in-person support.

Predictors of Treatment Reaction

Research is focused on individualized depression lithium treatment for depression. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective medications to treat each patient. In particular, pharmacogenetics identifies genetic variants that determine how the body's metabolism reacts to antidepressants. This enables doctors to choose the medications that are most likely to work best for each patient, reducing the time and effort in trials and errors, while eliminating any side effects that could otherwise slow advancement.

Another approach that is promising is to build models for prediction using multiple data sources, such as the clinical information with neural imaging data. These models can then be used to determine the best combination of variables that are predictive of a particular outcome, such as whether or not a medication will improve the mood and symptoms. These models can also be used to predict the patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of the treatment currently being administered.

A new generation of studies uses machine learning methods such as supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and improve the accuracy of predictive. These models have shown to be effective in predicting treatment outcomes such as the response to antidepressants. These approaches are becoming more popular in psychiatry and could become the norm in the future medical practice.

In addition to ML-based prediction models The study of the underlying mechanisms of depression continues. Recent findings suggest that the disorder is linked with neurodegeneration in particular circuits. This theory suggests that an individualized treatment for depression will depend on targeted therapies that restore normal functioning alternative ways to treat depression these circuits.

Internet-based interventions are a way to accomplish this. They can offer an individualized and tailored experience for patients. One study discovered that a web-based treatment was more effective than standard care in reducing symptoms and ensuring an improved quality of life for patients suffering from MDD. In addition, a controlled randomized study of a customized approach to depression treatment showed sustained improvement and reduced side effects in a significant proportion of participants.

Predictors of side effects

In the treatment of depression the biggest challenge is predicting and determining which antidepressant medication will have no or minimal adverse effects. Many patients are prescribed a variety of medications before settling on a treatment that is both effective and well-tolerated. Pharmacogenetics provides an exciting new way to take an efficient and specific approach to choosing antidepressant medications.

Several predictors may be used to determine which antidepressant is best to prescribe, including gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and the presence of comorbidities. However it is difficult to determine the most reliable and accurate predictors for a particular treatment is likely to require randomized controlled trials of significantly larger numbers of participants than those typically enrolled in clinical trials. This is due to the fact that the identification of interaction effects or moderators may be much more difficult in trials that only focus on a single instance of treatment per patient instead of multiple episodes of treatment over time.

In addition, predicting a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's own experience of tolerability and effectiveness. Currently, only some easily measurable sociodemographic and clinical variables appear to be reliably associated with response to MDD factors, including age, gender race/ethnicity, BMI, the presence of alexithymia, and the severity of depression symptoms.

Many issues remain to be resolved in the use of pharmacogenetics for depression treatment. first line treatment for anxiety and depression is a thorough understanding of the underlying genetic mechanisms is essential, as is an understanding of what is a reliable predictor of treatment response. Ethics like privacy, and the responsible use of genetic information are also important to consider. In the long run, pharmacogenetics may offer a chance to lessen the stigma that surrounds mental health care and improve the treatment outcomes for patients with depression. As with any psychiatric approach it is crucial to take your time and carefully implement the plan. For now, the best option is to provide patients with a variety of effective alternative depression treatment options medication options and encourage them to speak with their physicians about their concerns and experiences.